Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics and Roche presented new findings at the ICNMD, showing that SRP-9001 exhibits significant functional benefits for Duchenne muscular dystrophy patients. In a study with 20 participants, SRP-9001-treated individuals improved by 4 points on the NSAA at 52 weeks, with p-values demonstrating strong statistical significance (p<0.0001). Additionally, long-term data revealed no decline in function among older patients, showcasing a 7-point increase above baseline. The safety profile remains consistent across over 80 patients treated, reinforcing confidence in the ongoing Phase 3 EMBARK study.
Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast on July 6, 2022, to present new functional data from the clinical trials of SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD). The company will share an integrated analysis of one-year data across three studies (101, 102, and 103) involving participants who received the target dose of SRP-9001, comparing results to an external control group. The event will be accessible via their investor relations website.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced the granting of equity awards to 40 new employees as part of its 2014 Employment Commencement Incentive Plan. This decision aligns with Nasdaq Listing Rule 5635(c)(4). In total, options for 35,650 shares and 18,350 restricted stock units (RSUs) were awarded. The options have an exercise price of $74.96, matching the closing stock price on the grant date of June 30, 2022. Vesting occurs over four years, contingent on ongoing employment.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced a clinical hold on its investigational drug SRP-5051 (vesleteplirsen) by the FDA due to a serious adverse event of hypomagnesemia. This hold affects Part B of Study 5051-201 (MOMENTUM), which targets Duchenne muscular dystrophy. The company aims to provide requested safety information to the FDA promptly and is focused on resuming recruitment and dosing as soon as possible. Approximately half of the planned patients are enrolled, with completion expected by year-end.
Sarepta Therapeutics (NASDAQ: SRPT) announced the appointment of Michael Chambers and Dr. Kathryn Boor to its Board of Directors, enhancing its leadership team. Chambers, co-founder of Aldevron, brings extensive bioscience expertise, while Dr. Boor contributes her background in agriculture, sustainability, and governance. The company aims to advance its mission in precision genetic medicine for rare diseases, emphasizing a strategic vision to develop transformative therapies.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 10:00 a.m. P.T. The event will take place at the Terranea Resort, Rancho Palos Verdes, CA. This presentation will be webcast live and archived for 90 days for investor access. Sarepta focuses on developing precision genetic medicine and has over 40 programs in various stages for rare diseases, especially in Duchenne Muscular Dystrophy (DMD).
Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards on May 31, 2022, as part of its 2014 Employment Commencement Incentive Plan. The company provided options to purchase 90,900 shares and 46,625 restricted stock units (RSUs) to 70 new employees. The options have an exercise price of $72.82 per share, equal to the stock's closing price on the grant date. Vesting occurs over four years for both options and RSUs, subject to continued employment.
Sarepta Therapeutics reported Q1 2022 revenues of $210.8 million, a 51% increase year-over-year, with net product revenues reaching $188.8 million. The company's three therapies contributed to this growth, particularly the ongoing success of AMONDYS 45, launched in February 2021. Despite a net loss of $105 million or $1.20 per share, this is an improvement from a loss of $167.3 million in Q1 2021. Sarepta maintains a strong cash position with over $2 billion on its balance sheet for further investments.
Sarepta Therapeutics (NASDAQ:SRPT) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 9:20 a.m. P.T. The event will take place at the Encore Hotel in Las Vegas, Nevada, and will be webcast live on the company's investor relations website. This discussion will cover Sarepta's commitment to developing precision genetic medicine for rare diseases, as well as their extensive pipeline, which includes over 40 programs targeting Duchenne muscular dystrophy and limb-girdle muscular dystrophies. The webcast will remain archived for 90 days.
Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 44 newly hired individuals on April 29, 2022. The awards, part of the 2014 Employment Commencement Incentive Plan, include options for 48,525 shares and 24,875 restricted stock units (RSUs). The options have an exercise price of $72.32, aligning with the company's stock closing price on the Grant Date. Vesting will occur over four years, contingent on continued employment. Sarepta continues to lead in precision genetic medicine, focusing on rare diseases like Duchenne muscular dystrophy.